Literature DB >> 10519421

A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.

A Bandyopadhyay1, Y Zhu, M L Cibull, L Bao, C Chen, L Sun.   

Abstract

Transforming growth factor beta (TGF-beta) can promote late stage tumor progression in a number of model systems. In the present study, we have examined whether expression of a truncated soluble extracellular domain of TGF-beta type III receptor (sRIII) in human breast cancer MDA-MB-231 cells can antagonize the tumor-promoting activity of TGF-beta by sequestering active TGF-beta isoforms that are produced by the cancer cells. The secretion of sRIII reduced the amount of active TGF-beta1 and TGF-beta2 in the conditioned medium. This led to a significant reduction of the growth-inhibitory activity of the medium conditioned by sRIII-expressing cells on the growth of mink lung epithelial CCL64 cells in comparison with the medium conditioned by the control cells. The tumor incidence and growth rate of all of the three sRIII-expressing clones studied were significantly lower than those of the control cells in athymic nude mice. Four of five control cell-inoculated mice showed spontaneous metastasis in the lung, whereas none of the sRIII-expressing cell-inoculated mice had any lung metastasis. Thus, our results suggest that the sRIII may be used to antagonize the tumor-promoting activity of TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519421

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

Review 1.  TGF-beta antagonists: why suppress a tumor suppressor?

Authors:  Rosemary J Akhurst
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p8 gene expression.

Authors:  A C García-Montero; S Vasseur; L E Giono; E Canepa; S Moreno; J C Dagorn; J L Iovanna
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Cancer Microenviron       Date:  2011-07-12

4.  A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.

Authors:  Alicia M Viloria-Petit; Laurent David; Jun Yong Jia; Tuba Erdemir; Anita L Bane; Dushanthi Pinnaduwage; Luba Roncari; Masahiro Narimatsu; Rohit Bose; Jason Moffat; John W Wong; Robert S Kerbel; Frances P O'Malley; Irene L Andrulis; Jeffrey L Wrana
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

5.  Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer.

Authors:  Paul T Winnard; Jessica B Kluth; Venu Raman
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

6.  Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.

Authors:  Y-S Jang; G-Y Seo; J-M Lee; H-Y Seo; H-J Han; S-J Kim; B-R Jin; H-J Kim; S-R Park; K-J Rhee; W-S Kim; P-H Kim
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

Review 7.  Targeting the transforming growth factor-beta signaling pathway in human cancer.

Authors:  Nagathihalli S Nagaraj; Pran K Datta
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

8.  Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Authors:  Kaye L Stenvers; Melinda L Tursky; Kenneth W Harder; Nicole Kountouri; Supavadee Amatayakul-Chantler; Dianne Grail; Clayton Small; Robert A Weinberg; Andrew M Sizeland; Hong-Jian Zhu
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

9.  Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.

Authors:  Valentín Mendoza; M Magdalena Vilchis-Landeros; Guillermo Mendoza-Hernández; Tao Huang; Maria M Villarreal; Andrew P Hinck; Fernando López-Casillas; Jose-Luis Montiel
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

10.  Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor.

Authors:  Erik V Verona; Yuping Tang; Thomas K Millstead; Andrew P Hinck; Joseph K Agyin; Lu-Zhe Sun
Journal:  Protein Eng Des Sel       Date:  2008-05-21       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.